5MOH
Crystal structure of CK2alpha with ZT0583 bound.
Summary for 5MOH
| Entry DOI | 10.2210/pdb5moh/pdb |
| Descriptor | Casein kinase II subunit alpha, 2-(3-methoxy-4-oxidanyl-phenyl)ethanoic acid, ACETATE ION, ... (4 entities in total) |
| Functional Keywords | ck2alpha, ck2a, fragment based drug discovery, high concentration screening, selective atp competitive inhibitors, surface entrophy reduction, transferase |
| Biological source | Homo sapiens (Human) |
| Cellular location | Nucleus : P68400 |
| Total number of polymer chains | 1 |
| Total formula weight | 39331.65 |
| Authors | Brear, P.,De Fusco, C.,Georgiou, K.,Iegre, J.,Sore, H.,Hyvonen, M.,Spring, D. (deposition date: 2016-12-14, release date: 2017-05-24, Last modification date: 2024-01-17) |
| Primary citation | De Fusco, C.,Brear, P.,Iegre, J.,Georgiou, K.H.,Sore, H.F.,Hyvonen, M.,Spring, D.R. A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066. Bioorg. Med. Chem., 25:3471-3482, 2017 Cited by PubMed Abstract: Recently we reported the discovery of a potent and selective CK2α inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket). Here we describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy. Specifically, we aimed to develop inhibitors by linking a high-affinity fragment anchored in the αD site to a weakly binding warhead fragment occupying the ATP site. Moreover, we describe the remarkable impact that molecular modelling had on the development of this novel chemical tool. The work described herein shows potential for the development of a novel class of CK2 inhibitors. PubMed: 28495381DOI: 10.1016/j.bmc.2017.04.037 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.38 Å) |
Structure validation
Download full validation report
